Skip to main content

Truist Financial Corp. Value Stock - Dividend - Research Selection

Bbandt

ISIN: US89832Q1094 , WKN: A2PWMZ

Market price date:
Market price:  


Fundamental data and company key figures of the share

Annual reports in
Key figures
Cash flow
Net operating cash flow
Capital Expenditures
Free cash flow
Balance sheet
Total Equity
Liabilities & Shareholders equity
Income statement
Net income
Eps (diluted)
Diluted shares outstanding
Net sales/revenue

Fundamental ratios calculated on:

Ratios
Key figures
Cash flow
P/C
 
P/FC
Balance sheet
ROI
ROE
Income statement
P/E
Div. Yield %
P/B
P/S


Do you want to do make a detailed fundamental analysis of this stock?

✓ NEW Fundamental API Access to 500 data points per month
Fundamental data up to 25 years
Comparison to all other stocks by the FScore
Time saving!

How our site works ...

Non-binding 7 days without automatic subscription
 No termination required after the free week
Finanzoo fundamental analysis
Data updated daily
Virtual depots
Share alarms via email
Subscription can be canceled at any time at the end of the month 
Choice of desired shares
Over 2000 stock analyzes available
Bitcoin payment possible if you do not want to subscribe

Price for monthly subscription $ 19.99 / month including VAT.



Description Data
Symbol
Market Capitalization USD
Country
Indices
Sectors
Raw Data Source
Stock Split
Internet


Description of the company

BB&T Corporation operates as a financial holding company that provides various banking and trust services for small and mid-size businesses, public agencies, local governments, and individuals. The company operates through four segments: CB-Retail, CB-Commercial, IH&PF, and FS&CF. Its deposit products include noninterest-bearing checking, interest-bearing checking, savings, and money market deposit accounts, as well as certificates of deposit and individual retirement accounts. The company also provides various funding services; and asset management, automobile lending; bankcard lending; consumer finance; home equity and mortgage lending; insurance, such as property and casualty, life, health, employee benefits, commercial general liability, surety, title and other insurance products; investment brokerage; mobile/online banking; and payment, lease financing, small business lending, and wealth management/private banking services. In addition, it offers association, capital markets, institutional trust, insurance premium and commercial finance, international banking, leasing, merchant, commercial deposit and treasury, commercial middle market lending, floor plan lending, commercial mortgage lending, mortgage warehouse lending, private equity investments, real estate lending, and supply chain management services. Further, the company provides retail brokerage, equity and debt underwriting, investment advice, corporate finance, and equity research services, as well as facilitates the origination, trading, and distribution of fixed-income securities and equity products. Additionally, BB&T Corporation offers non-deposit investment products, including discount brokerage services, equities, fixed-rate, variable-rate and index annuities, mutual funds, government and municipal bonds, and money market funds. As of December 31, 2017, it operated 2,049 offices. The company was founded in 1872 and is headquartered in Winston-Salem, North Carolina.

The Finanzoo GmbH assumes no liability for the accuracy of the information! All information is provided without warranty. Sources:: www.bundesanzeiger.de, www.sec.gov,


NEWS


IQVIA Holdings Inc. (IQV) Offers Impressive Upside Despite AI-Linked Threats

2026-02-24
IQVIA Holdings Inc. (NYSE:IQV) is one of the 10 best life sciences stocks to buy according to hedge funds. On February 19, Jailendra Singh from Truist Financial reiterated his Buy rating for IQVIA Holdings Inc. (NYSE:IQV). He lowered the price target on the stock from $290 to $274, which still offers an impressive upside potential […]

Wells Fargo Lowers PT on PayPal Holdings, Inc. (PYPL)

2026-02-24
PayPal Holdings, Inc. (NASDAQ:PYPL) is one of the Cheap NASDAQ Stocks To Buy in 2026. On February 19, Jason Kupferberg from Wells Fargo reiterated a Hold rating on the stock and lowered the price target from $58 to $48. Earlier on February 10, Matthew Coad from Truist Financial downgraded PayPal Holdings, Inc. (NASDAQ:PYPL) to Sell […]

How The Enhabit (EHAB) Investment Narrative Is Shifting After The Kinderhook Cash Takeover Offer

2026-02-24
Enhabit’s updated fair value price target has shifted from US$11.75 to US$13.08, bringing it closer to the US$13.80 per share all cash offer on the table. Street research has rapidly recalibrated around this deal price, with many analysts adjusting targets to sit near the takeout level and reframing their ratings and narratives accordingly. As you read on, you will see how this evolving analyst story can help you track what matters most for Enhabit from here. Stay updated as the Fair Value...

How The L3Harris Technologies (LHX) Investment Story Is Shifting With Missile Spinout And Pentagon Funding

2026-02-24
L3Harris Technologies has just seen its modeled fair value edge up from US$380.63 to US$382.37 per share, a small change that still matters if you are tracking where analysts think the stock should sit. That shift is tied to a wave of refreshed research after the missile solutions spinout announcement and the planned US$1b preferred equity investment from the Department of War, with several bullish voices lifting their targets. As you read on, you will see how this evolving analyst narrative...

Truist Could Soar If These 2 Things Go Right

2026-02-24
Keep an eye on the bank's revenues, rising margins, and stock buybacks in 2026.

How The Story On Harmony Biosciences (HRMY) Is Shifting With Wakix Legal And Generic Risks

2026-02-24
Harmony Biosciences Holdings is back in focus after a modest lift in fair value estimates, from about US$46.45 to roughly US$47.30 per share. That small adjustment sits against a split analyst backdrop, with more supportive views anchored to Wakix cash flow assumptions and cautious voices concentrating on legal risks and the timing of potential generic entry. As you read on, you will see how these competing views shape the story and what to watch to stay on top of the evolving...

Truist Raises Cigna (CI) Price Target to $350, Sees Clearer Growth Outlook after Q4

2026-02-24
The Cigna Group (NYSE:CI) is included among the 13 Best Strong Buy Dividend Stocks to Invest in. On February 17, Truist raised its price recommendation on The Cigna Group (NYSE:CI) to $350 from $320. The firm reiterated a Buy rating on the stock. The analyst updated the firm’s model following the company’s Q4 results and its […]

How The Redwire (RDW) Investment Narrative Is Shifting With New Analyst Views And Contracts

2026-02-23
Redwire’s updated fair value price target now sits at US$13.11, a slight reset from US$13.22. That small move comes alongside fresh analyst research, where more constructive views are being weighed against concerns about near term catalysts, valuation, and execution risk. As you read on, you will see how to interpret these shifting calls and track the evolving Redwire story for yourself. Analyst Price Targets don't always capture the full story. Head over to our Company Report to find new...

Truist Lowers Neurocrine Biosciences, Inc.’s (NBIX) PT Following 2026 Outlook Update

2026-02-23
Neurocrine Biosciences, Inc. (NASDAQ:NBIX) is among the 7 Oversold Pharma Stocks to Buy Now. Neurocrine Biosciences, Inc. (NASDAQ:NBIX) is one of the most oversold stocks. TheFly reported on February 17 that Truist reduced its price target on NBIX to $140 from $169 and maintained a Buy rating on the stock. The increase came after management’s 2026 projection, and the company’s fourth-quarter results were […]

Here is Why Edwards Lifesciences Corporation (EW) Looks Attractive

2026-02-23
Edwards Lifesciences Corporation (NYSE:EW) is one of the 10 best healthcare equipment stocks to buy according to hedge funds. On February 11, Richard Newitter from Truist Financial reduced the price target on Edwards Lifesciences Corporation (NYSE:EW) from $92 to $89. The analyst reaffirmed his Hold rating on the stock that offers a revised upside potential […]